Cargando…
Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes
OBJECTIVE: Early results of a randomised trial showed reduced fibrosis due to recurrent HCV hepatitis with tacrolimus triple therapy (TT) versus monotherapy (MT) following transplantation for HCV cirrhosis. We evaluated the clinical outcomes after a median 8 years of follow-up, including differences...
Autores principales: | Manousou, Pinelopi, Cholongitas, Evangelos, Samonakis, Dimitrios, Tsochatzis, Emmanuel, Corbani, Alice, Dhillon, A P, Davidson, Janice, Rodríguez-Perálvarez, Manuel, Patch, D, O'Beirne, J, Thorburn, D, Luong, TuVinh, Rolles, K, Davidson, Brian, McCormick, P A, Hayes, Peter, Burroughs, Andrew K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033276/ https://www.ncbi.nlm.nih.gov/pubmed/24131637 http://dx.doi.org/10.1136/gutjnl-2013-305606 |
Ejemplares similares
-
Nine scoring models for short-term mortality in alcoholic hepatitis: cross-validation in a biopsy-proven cohort
por: Papastergiou, V, et al.
Publicado: (2014) -
Utilization of Mycophenolic Acid, Azathioprine, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus: Multinational Study
por: Sahman, Majda, et al.
Publicado: (2021) -
The human liver microenvironment shapes the homing and function of CD4(+) T-cell populations
por: Wiggins, Benjamin G, et al.
Publicado: (2022) -
An interaction between tacrolimus and pristinamycin resulting in an elevated tacrolimus level
por: Tehan, Jane V., et al.
Publicado: (2011) -
Tacrolimus: COVID-19 and toxic levels of tacrolimus: case report
Publicado: (2021)